{
  "id": "myasthenia-gravis",
  "title": "Myasthenia Gravis",
  "lang": "en",
  "source_lang": "en",
  "summary": "Myasthenia gravis is an autoimmune disorder of nerve-to-muscle signaling that causes fluctuating skeletal muscle weakness, often affecting the eyes, swallowing, limbs, or breathing.",
  "category": "health",
  "subcategory": "diseases",
  "type": "concept",
  "aliases": [
    "MG",
    "autoimmune myasthenia gravis"
  ],
  "generated_at": "2026-11-03",
  "model": "pro/gpt-6.1-sol",
  "url": "https://aiwiki.page/en/myasthenia-gravis/",
  "translations": {
    "zh-Hans": {
      "url": "https://aiwiki.page/zh/myasthenia-gravis/",
      "json": "https://aiwiki.page/zh/myasthenia-gravis.json"
    }
  },
  "sections": [
    {
      "heading": "",
      "text": "Myasthenia gravis is a chronic autoimmune disease in which impaired transmission at the neuromuscular junction causes fluctuating weakness of skeletal muscles. Weakness typically increases with repeated or sustained activity and improves with rest. Eye movements, eyelid elevation, facial expression, chewing, swallowing, speech, limb movement, and breathing may be affected. The disorder ranges from weakness confined to the eye muscles to generalized disease with potentially life-threatening respiratory involvement. Despite its name, which historically conveyed “grave muscle weakness,” modern treatment allows many affected people to achieve substantial symptom control."
    },
    {
      "heading": "Mechanism",
      "text": "At a normal neuromuscular junction, a motor nerve releases acetylcholine, which binds to receptors on the muscle membrane and initiates the electrical activity needed for contraction. In myasthenia gravis, the immune system produces antibodies against proteins involved in this process, reducing the reliability of nerve-to-muscle signaling.\n\nThe most common targets are acetylcholine receptors. Antibodies against these receptors can activate the complement system, damage the postsynaptic membrane, accelerate receptor removal, and interfere with receptor function. The resulting reduction in the junction’s normal safety margin helps explain why repeated activity can produce increasing weakness.\n\nOther patients have antibodies against muscle-specific kinase, usually abbreviated MuSK, a protein essential for organizing acetylcholine receptors. MuSK antibodies mainly disrupt signaling required to maintain the junction rather than producing the same complement-mediated injury typical of acetylcholine receptor antibodies. Antibodies against low-density lipoprotein receptor-related protein 4, or LRP4, are found in a smaller group.\n\nSome clinically established cases have no detectable antibodies on standard tests. These are described as seronegative, although more sensitive testing may identify antibodies in some of them.\n\nRole of the thymus\n\nThe thymus contributes to immune tolerance and is closely associated with some forms of myasthenia gravis. Many patients with acetylcholine receptor antibodies have thymic abnormalities, including lymphoid hyperplasia. A minority have a thymoma, a tumor arising from thymic epithelial cells.\n\nThese associations do not mean that all patients have thymic disease or that thymoma is necessary for myasthenia gravis to develop."
    },
    {
      "heading": "Clinical features and forms",
      "text": "The defining feature is fatigable weakness, rather than generalized tiredness alone. Symptoms can vary over hours, between days, and across the course of the disease. Sensation is usually preserved, pupils are generally unaffected, and tendon reflexes are typically retained.\n\nOcular myasthenia\n\nOcular myasthenia affects the muscles controlling eye movements and eyelid elevation. Common manifestations are drooping of one or both eyelids and double vision. The pattern may be asymmetric and may change over time.\n\nSome patients remain limited to ocular disease. Others subsequently develop weakness outside the eye muscles, particularly during the early years after symptom onset.\n\nGeneralized myasthenia\n\nGeneralized disease involves muscles beyond those controlling the eyes and eyelids. Manifestations may include:\n\n- Facial weakness and reduced facial expression.\n- Difficulty chewing, especially during prolonged meals.\n- Swallowing difficulty and impaired handling of saliva.\n- Nasal or slurred speech, including dysarthria.\n- Neck weakness, sometimes causing difficulty holding the head upright.\n- Weakness of the arms or legs, often more noticeable in proximal muscles.\n- Weakness of respiratory muscles.\n\nMuSK-associated disease often has prominent facial, swallowing, speech, neck, or respiratory involvement, although clinical patterns overlap among antibody groups.\n\nMyasthenic crisis\n\nA myasthenic crisis is a severe exacerbation in which respiratory or bulbar weakness causes respiratory failure requiring ventilatory support. Bulbar weakness can also impair airway protection and increase the risk of aspiration. Crisis is a medical emergency.\n\nInfections, operations, changes in treatment, and certain medications can precipitate deterioration, although an identifiable trigger is not always present. Mechanical ventilation may be necessary while treatment restores neuromuscular function."
    },
    {
      "heading": "Diagnosis",
      "text": "Diagnosis combines a characteristic clinical pattern with antibody testing and physiological evidence of impaired neuromuscular transmission. No single test detects every case.\n\nClinical assessment\n\nA medical history and neurological examination establish the distribution, fluctuation, and fatigability of weakness. Sustained gaze or repeated movements may reveal increasing weakness. An ice-pack test can temporarily improve a drooping eyelid in some patients and provide supportive evidence, but it is not definitive by itself.\n\nAntibody testing\n\nBlood tests commonly assess acetylcholine receptor antibodies, followed by MuSK antibodies when appropriate. Selected laboratories also test for LRP4 antibodies or use specialized cell-based assays.\n\nA negative result does not exclude the disease, particularly in ocular myasthenia. Conversely, antibody findings must be interpreted alongside the clinical picture. Antibody concentration does not consistently track disease severity in an individual.\n\nElectrophysiology\n\nElectrophysiological testing evaluates neuromuscular transmission:\n\n- Repetitive nerve stimulation may show a decrement in the muscle response during repeated stimulation.\n- Single-fiber electromyography measures variability in transmission timing, termed jitter. It is highly sensitive in suitable circumstances but is not specific to myasthenia gravis.\n\nThe muscles examined, technical methods, and clinical context affect interpretation.\n\nImaging and differential diagnosis\n\nChest imaging, usually computed tomography, is used to assess the thymus and investigate possible thymoma.\n\nThe differential diagnosis includes Lambert–Eaton myasthenic syndrome, botulism, congenital myasthenic syndromes, muscle diseases, motor neuron disease, and disorders affecting cranial nerves or the brainstem. Congenital myasthenic syndromes are inherited disorders of neuromuscular transmission, not autoimmune myasthenia gravis, and their treatment differs."
    },
    {
      "heading": "Treatment",
      "text": "Treatment depends on disease distribution, severity, antibody subtype, thymic findings, and other medical conditions. Its main approaches are improving neuromuscular transmission, reducing pathogenic immune activity, and treating severe exacerbations.\n\nSymptomatic treatment\n\nPyridostigmine inhibits acetylcholinesterase, the enzyme that breaks down acetylcholine. This prolongs acetylcholine availability at the neuromuscular junction and can improve muscle strength without directly treating the autoimmune process.\n\nIts effectiveness varies by disease subtype, and it may be less effective or less well tolerated in MuSK-associated disease. Adverse effects include abdominal cramping, diarrhea, increased secretions, and slowing of the heart rate.\n\nImmunotherapy\n\nCorticosteroids and other immune-modifying medicines can reduce disease activity. Commonly used longer-term agents include azathioprine and mycophenolate mofetil. Some treatments take months to achieve their full effect. Corticosteroid initiation can occasionally cause temporary worsening.\n\nTargeted therapies address particular components of the disease process:\n\n- Complement inhibitors reduce complement-mediated injury in eligible patients with acetylcholine receptor antibody-positive generalized disease.\n- Therapies targeting the neonatal Fc receptor accelerate the removal of circulating immunoglobulin G, including pathogenic antibodies.\n- Rituximab, a monoclonal antibody that depletes certain B cells, is used particularly in MuSK-associated disease and in selected other cases.\n\nEligibility and regulatory approvals differ by medicine and jurisdiction. Infection risks and other adverse effects vary with the immune pathway targeted.\n\nRapid-acting treatment\n\nPlasma exchange, a form of apheresis, removes circulating antibodies and other plasma components. Intravenous immunoglobulin modifies immune activity through several mechanisms. Both are used for significant exacerbations, crisis, or selected circumstances requiring relatively rapid improvement. Their effects are generally temporary rather than curative.\n\nThymectomy\n\nThymectomy is surgical removal of the thymus. It is generally part of treatment when a resectable thymoma is present. Evidence from a randomized controlled trial also supports benefit in selected patients with non-thymomatous, acetylcholine receptor antibody-positive generalized disease, including improved disease control and reduced corticosteroid requirements.\n\nThe benefit is not immediate, and evidence does not support applying the same indication indiscriminately to all antibody subtypes or purely ocular disease."
    },
    {
      "heading": "Epidemiology and course",
      "text": "Myasthenia gravis is uncommon but occurs worldwide and at any age. Age and sex patterns vary between populations; younger adult cases are more often female, while later-onset disease increasingly affects men. Reported prevalence varies with population structure, diagnostic practices, and case ascertainment.\n\nThe course is variable. Periods of worsening may alternate with stable disease or remission, with or without ongoing medication. Complete, sustained remission without treatment occurs in some patients but cannot be assumed. Residual weakness, treatment adverse effects, and fluctuating functional limitations can affect quality of life even when severe exacerbations are controlled."
    },
    {
      "heading": "Pregnancy and neonatal disease",
      "text": "The course during pregnancy is variable: symptoms may improve, remain stable, or worsen, including after delivery. Maternal antibodies can cross the placenta and cause transient neonatal myasthenia, with weakness, feeding difficulty, or respiratory involvement in the newborn. This usually resolves as maternal antibodies are cleared.\n\nTransient neonatal myasthenia is distinct from inherited congenital myasthenic syndromes. Autoimmune myasthenia gravis is not generally inherited as a single-gene disorder, although genetic susceptibility contributes to disease risk."
    }
  ],
  "links": [
    "autoimmune-disease",
    "neuromuscular-junction",
    "acetylcholine",
    "immune-system",
    "antibody",
    "complement-system",
    "thymus",
    "thymoma",
    "dysarthria",
    "diagnosis",
    "medical-history",
    "x-ray-computed-tomography",
    "differential-diagnosis",
    "corticosteroid",
    "neonatal-fc-receptor",
    "monoclonal-antibody",
    "apheresis",
    "randomized-controlled-trial",
    "prevalence",
    "quality-of-life",
    "pregnancy"
  ],
  "sources": [],
  "license": "https://creativecommons.org/licenses/by/4.0/"
}